Strong cooperation with Weizmann Institute of Science
from left to right.: Michael Baumann, Chairman and Scientific Director DKFZ, Daniel Zajfmann, President Weizmann Instituts, Eran Elinav, Head of the bridging division, Josef Puchta, Administrative Director DKFZ
© DKFZ
DKFZ and the Weizmann Institute of Science (WIS) wish to combine their strengths and establish a strong cooperation in cancer-related microbiome research. Both institutions agreed to establish a bridging division at DKFZ. Eran Elinav, Professor at WIS, will receive the status of a Visiting/Guest Scientist at DKFZ and will head the bridging division from beginning of 2019. The main focus of the bridging division will rely on cancer-related microbiome research and collaborative projects together with other DKFZ groups.
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
